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Abstract Phospholipase A2 receptor (PLA2R) mediates various
biological responses elicited by group IB secretory phospholipase
A2 (sPLA2-IB). The recently cloned group X sPLA2 (sPLA2-X)
possesses several structural features characteristic of sPLA2-IB.
Here, we detected a specific binding site of sPLA2-X in mouse
osteoblastic MC3T3-E1 cells. Cross-linking experiments demon-
strated its molecular weight (180 kDa) to be similar to that of
PLA2R. In fact, sPLA2-X was found to bind the recombinant
PLA2R expressed in COS-7 cells, and its specific binding
detected in mouse lung membranes was abolished by the
deficiency of PLA2R. These findings demonstrate sPLA2-X to
be one of the high-affinity ligands for mouse PLA2R. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Secretory phospholipase A2s (sPLA2s) are a growing family
of enzymes that hydrolyze the sn-2 fatty acid ester bonds of
glycerophospholipids to produce free fatty acids and lyso-
phospholipids [1,2]. sPLA2s have several common character-
istics including a relatively low molecular mass (13^18 kDa),
the presence of 6 to 8 disul¢de bridges and an absolute cata-
lytic requirement for millimolar concentrations of Ca2 [3,4].
At present, mammalian sPLA2s are classi¢ed into nine di¡er-
ent groups depending on the primary structure characterized
by the number and positions of cysteine residues [3,5^9].
Among them, the group II subfamily (IIA, IID, IIE and V)
is thought to play a role in the production of several lipid
mediators especially in the delayed phase of the cell activation
process, because their expression levels are up-regulated under
various in£ammatory conditions [6,7,10,11]. In contrast,
group IB sPLA2 (sPLA2-IB) has long been thought to be a
digestive enzyme, given its abundance in the pancreas. How-
ever, the discovery of the PLA2 receptor (PLA2R) has ex-
panded our concept of sPLA2-IB [12]. In addition to its di-
gestive function, sPLA2-IB exerts various biological responses,
including cell proliferation and lipid mediator releases,
through binding to PLA2R [13]. The PLA2R is composed of
a large extracellular portion including a characteristic tandem
repeat of eight carbohydrate recognition domains, and its
overall molecular organization is related to a unique member
of the C-type animal lectin family, including the macrophage
mannose receptor [14]. Our recent studies with PLA2R-de¢-
cient mice have demonstrated its critical role in the produc-
tion of pro-in£ammatory cytokines during the progression of
endotoxic shock [15,16]. In the ligand^receptor relationship,
there is a strict species speci¢city and sPLA2-IB was identi¢ed
as an endogenous ligand of PLA2R, at least in rats and mice
[17]. Group IIA sPLA2 (sPLA2-IIA) can also bind PLA2R
with about 10-fold lower a⁄nity compared to sPLA2-IB
[17], whereas group IID sPLA2 can not act as a ligand in
spite of its structural similarities with sPLA2-IIA [18].
The recently cloned group X sPLA2 (sPLA2-X) possesses
several structural features characteristic of other sPLA2s [5]. It
has 16 cysteine residues located at positions characteristic of
both sPLA2-IB and sPLA2-IIA, an amino acid C-terminal
extension that is typical of sPLA2-IIA, and a propeptide se-
quence attached at NH2-terminals similar to sPLA2-IB. We
and other groups have recently shown that sPLA2-X possesses
a powerful hydrolyzing activity toward phosphatidylcholine
and elicits a marked release of arachidonic acid from several
intact cell membranes [19,20]. Considering the structural sim-
ilarities of sPLA2-X with sPLA2-IB and IIA, knowing about
its potency as a ligand for PLA2R is indispensable for under-
standing its physiological and pathological functions. In the
present study, we puri¢ed mouse sPLA2-X and examined its
binding characteristics in mouse osteoblastic MC3T3-E1 cells
that possess high levels of native PLA2R [21]. Further binding
studies in recombinant PLA2R-expressing cells and in
PLA2R-de¢cient mice also demonstrated that sPLA2-X is
one of the high-a⁄nity ligands for murine PLA2R.
2. Materials and methods
2.1. Materials
Sodium [125I]iodine (carrier-free, 3.7 GBq/ml) was purchased from
Amersham Pharmacia Biotech. Puri¢ed recombinant human sPLA2-
IB, IIA and X were prepared as described previously [19]. Porcine
pancreatic sPLA2-IB was obtained from Boehringer Mannheim. Di-
succinidyl suberate (DSS) was purchased from Pierce Chemical Co.
Indoxam was synthesized at Shionogi Research Laboratories [22].
2.2. Recombinant expression and puri¢cation of mouse pro- and mature
sPLA2-X
Mouse sPLA2-X cDNA was isolated from mouse spleen by poly-
merase chain reaction based on the human sPLA2-X sequence [5],
which was then inserted into pcDNA3.1(+) (Invitrogen) to construct
the expression plasmid. Transfection into Chinese hamster ovary cells,
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selection of stably expressing clones, collection of the conditioned
medium and puri¢cation with an antibody-coupled a⁄nity column
were performed as described for human sPLA2-X [19], based on the
cross-reactivity of anti-human sPLA2-X antibody with mouse enzyme.
Analysis of the ¢nal reverse-phase high performance liquid chroma-
tography preparations by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) revealed the existence of two species of
sPLA2-X, and NH2-terminal sequence analysis with an Applied Bio-
systems Procise Sequencer revealed them to be a mature form of
sPLA2-X (13 kDa) and its pro-form (14 kDa) having a propeptide
sequence at the NH2 terminus.
2.3. Binding experiments
Iodination of mouse sPLA2-X and porcine sPLA2-IB was per-
formed by the chloramine T method as described previously [23]
and the speci¢c radioactivity of 125I-sPLA2-X and 125I-sPLA2-IB
were 1200 and 1100 cpm/fmol, respectively. MC3T3-E1 cells
(ATCC) were cultured in 24-well plates in 10% FCS/DMEM. At
con£uence, the cells were washed three times with phosphate-bu¡ered
saline (PBS) and incubated with various concentrations of mouse 125I-
sPLA2-X in 0.4 ml of the binding bu¡er (Hanks’ balanced salt solu-
tion, pH 7.4, containing 0.1% BSA) for 2 h at 4‡C. After the incuba-
tion, cells were washed with PBS three times, and the cell-bound
radioactivity was measured. Speci¢c binding was determined as the
di¡erences between the presence and absence of 100 nM unlabelled
mouse sPLA2-X. Displacement experiments were performed by incu-
bating with 1.5 nM mouse 125I-sPLA2-X in the presence of various
concentrations of sPLA2 proteins under the same assay conditions as
described above. The IC50 value was evaluated from the inhibition
curves as the concentration that inhibits half of the speci¢c binding.
In separate experiments, the binding potency of sPLA2-X to mouse
recombinant PLA2R was examined as follows. The cDNA encoding
mouse PLA2R was transiently introduced into COS-7 cells with Fu-
Gene 6 reagent (Roche Diagnostics), and the binding activity of 125I-
sPLA2-X was evaluated as described above. The inhibitory e¡ect of
indoxam on sPLA2-X binding to PLA2R-expressing COS-7 cells was
examined by incubating with 2 nM 125I-sPLA2-X in the presence of
various concentrations of indoxam.
The generation of PLA2R-de¢cient mice was described in our pre-
vious paper [15] and they were backcrossed to C57BL/6J mice more
than eleven times. C57BL/6J mice matched for gender and age were
used as wild-type mice. Preparation of the crude lung membranes and
their binding assay with 125I-sPLA2-X (2 nM) was performed accord-
ing to the same protocol as the sPLA2-IB binding study described in
the previous report [15]. Speci¢c binding was determined as the di¡er-
ences between the presence and absence of unlabeled 100 nM mouse
PLA2-X.
2.4. A⁄nity cross-linking experiment
Con£uent MC3T3-E1 cells grown in 10-cm-diameter dishes were
incubated in 6 ml of binding medium containing 2 nM 125I-sPLA2-
X with or without 100 nM unlabelled mouse sPLA2-X for 2 h at 4‡C.
In separate experiments, the cells were incubated with 2 nM 125I-
sPLA2-IB with or without 500 nM unlabelled porcine sPLA2-IB.
After washing three times with Hanks’ medium, pH 7.6, cells were
incubated in 8 ml of Hanks’ medium containing 0.25 mM DSS for 30
min at room temperature. The reaction was stopped by the addition
of Tris/HCl (¢nal 50 mM, pH 7.4). The cells were harvested and
collected by centrifugation. They were lysed by adding 50 Wl of 1%
Triton X-100 containing a mixture of protease inhibitors (1 mM phen-
ylmethylsulfonyl £uoride, 2 mM EDTA and 20 Wg/ml leupeptin).
After centrifugation at 10 000Ug for 15 min, the resultant supernatant
was separated by SDS^PAGE with a 4^20% gradient SDS^polyacryl-
amide gel (Daiichi Pure Chemical, Tokyo). After electrophoresis, the
gel was dried and exposed to the imaging plate and read with a Fujix
BAS2000 bio-image analyzer.
3. Results
3.1. 125I-sPLA2-X binding to MC3T3-E1 cells
We prepared a highly active radioligand of mouse sPLA2-X
and examined its binding characteristics in MC3T3-E1 cells
that possess high levels of native PLA2R on the cell surface
[21]. As shown in Fig. 1A, a saturable and speci¢c binding of
mouse 125I-sPLA2-X was detected. Scatchard analysis of these
data (Fig. 1B) demonstrated the existence of a single class of
binding sites with an equilibrium dissociation constant (Kd) of
4.6 nM and a maximum binding capacity (Bmax) of 59.7 fmol/
106 cells (about 36 000 binding sites/cell), which coincided with
the Bmax value reported in the porcine sPLA2-IB binding to
the PLA2R in MC3T3-E1 cells [21]. Next, the speci¢city of the
sPLA2-X binding site was examined by evaluating the relative
inhibitory potencies of various sPLA2 proteins. As for the
mouse sPLA2-X species, pro-sPLA2-X blocked the binding
with about 10-fold weaker potency than the mature form of
sPLA2-X (Fig. 2). Porcine and human sPLA2-IB also strongly
blocked the sPLA2-X binding with IC50 values of 1.14 and
1.71 nM, respectively. Inversely, mouse sPLA2-X blocked the
porcine sPLA2-IB binding to the PLA2R in MC3T3-E1 cells
(data not shown). In both cases, human sPLA2-IIA showed a
much weaker suppressive e¡ect.
In order to characterize a high-a⁄nity binding site of 125I-
sPLA2-X, we performed the a⁄nity labeling experiments us-
ing a homobifunctional cross-link reagent, DSS. As shown in
Fig. 1. Equilibrium binding of 125I-sPLA2-X to MC3T3-E1 cells. A:
Saturation isotherm of 125I-sPLA2-X binding to MC3T3-E1 cells.
Speci¢c binding was calculated by subtracting the non-speci¢c bind-
ing from the total binding. B: Scatchard plot of the speci¢c 125I-
sPLA2-X binding. Each point represents the mean of duplicate mea-
surements. The data are representative of three experiments.
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Fig. 3, the 125I-sPLA2-X binding complex was speci¢cally de-
tected at an apparent molecular mass of 200 kDa only in the
treatment with DSS (lanes 4 and 6), which was completely
abolished in the presence of an excess amount of unlabeled
sPLA2-X protein (lane 3) as well as porcine sPLA2-IB (data
not shown). In a similar cross-linking experiment, the cross-
linked complex composed of sPLA2-IB (14 kDa) and PLA2R
(180 kDa) showed the same molecular weight in MC3T3-E1
cells (lanes 1 and 2). Thus, the binding speci¢city and bio-
chemical features of the sPLA2-X binding site strongly suggest
its relation to PLA2R.
3.2. 125I-sPLA2-X binding to recombinant PLA2R
In order to verify the identity of the sPLA2-X binding pro-
tein, we examined the binding potency of mouse sPLA2-X to
the recombinant mouse PLA2R transiently expressed in COS-
7 cells. As shown in Fig. 4A, a high amount of speci¢c sPLA2-
X binding was detected in the PLA2R-expressing COS-7 cells
in contrast to its absence in the mock-transfected cells. The
sPLA2-X binding was also blocked by porcine sPLA2-IB and
the speci¢c sPLA2-IB binding detected in the PLA2R-express-
Fig. 2. Displacement of 125I-sPLA2-X binding by sPLA2 proteins in
MC3T3-E1 cells. MC3T3-E1 cells were incubated with 1.5 nM 125I-
sPLA2-X in the presence of various concentrations of mouse mature
sPLA2-X (m-X), pro-sPLA2-X (pro m-X), porcine sPLA2-IB (p-IB),
human sPLA2-IB (h-IB), and human sPLA2-IIA (h-IIA) and the
speci¢c binding activity was measured. The results are expressed as
the percentage of 125I-sPLA2-X speci¢c binding in the absence of
these sPLA2s. Each point represents the mean of duplicate measure-
ments. The data are representative of three experiments.
Fig. 3. Characterization of the sPLA2-X binding site by a⁄nity
cross-linking. Binding assays were carried out at 4‡C for 2 h by in-
cubating MC3T3-E1 cells with 2 nM 125I-porcine sPLA2-IB in the
presence (lane 1) or absence (lane 2) of 500 nM of unlabelled por-
cine sPLA2-IB, or with 125I-mouse sPLA2-X in the presence (lanes 3
and 5) or absence (lanes 4 and 6) of 100 nM of unlabelled mouse
sPLA2-X. At the end of incubation, the cells were washed and
treated (lanes 1^4) or untreated (lanes 5 and 6) with 0.25 mM DSS
for 30 min and then analyzed as described in Section 2 under the
reduced conditions. Molecular weight markers are indicated on the
left.
Fig. 4. 125I-mouse sPLA2-X binding to mouse PLA2R expressed in
COS-7 cells. A: COS-7 cells transfected with PLA2R cDNA or vec-
tor alone were incubated with 2 nM 125I-mouse sPLA2-X in the ab-
sence (none) or presence of 300 nM of unlabelled mouse sPLA2-X
or porcine sPLA2-IB for 2 h at 4‡C, and the binding activity was
determined. B: PLA2R-expressing COS-7 cells were incubated with
1.5 nM 125I-sPLA2-X in the presence of various concentrations of
indoxam, and the speci¢c binding activity was measured. The results
are expressed as the percentage of 125I-sPLA2-X speci¢c binding in
the absence of indoxam. Each point represents the mean of dupli-
cate measurements. The data are representative of three experi-
ments.
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ing cells was completely blocked by mouse sPLA2-X (data not
shown). As shown in Fig. 4B, a sPLA2 speci¢c inhibitor in-
doxam [22] suppressed the sPLA2-X binding to mouse PLA2R
in a dose-dependent manner with an IC50 value of 670 nM.
Thus, these ¢ndings demonstrate that mouse sPLA2-X is one
of the natural ligands of mouse PLA2R.
3.3. 125I-sPLA2-X binding to mouse lung membranes
To check for the existence of other binding components of
sPLA2-X in mice, we examined the binding activity of 125I-
sPLA2-X in the crude lung membrane fractions and found a
considerable amount of its speci¢c binding (Fig. 5). The bind-
ing was saturable, speci¢c for sPLA2-X and displaceable by
sPLA2-IB (data not shown). In PLA2R-de¢cient mice that we
have recently generated [15], there was no signi¢cant binding
in the prepared lung membranes, demonstrating that PLA2R
represents the speci¢c binding site for sPLA2-X in mice.
4. Discussion
Since the discovery of PLA2R, sPLA2s have been thought
to act as signaling molecules for various biological responses
in addition to their enzymatic activities [12,13]. In the present
study, sPLA2-X was identi¢ed as a natural ligand of mouse
PLA2R in native and recombinant receptors. Since there is a
strict species speci¢city in the ligand^receptor relationship, the
binding a⁄nity of sPLA2-X for mouse PLA2R cannot be
directly compared with those of sPLA2-IB and IIA due to
the lack of these mouse enzymes. In previous binding studies
with snake venom Oxyuranus scutellatus toxin 1 as a radio-
ligand, mouse sPLA2-IB showed a similar binding a⁄nity for
mouse PLA2R with human sPLA2-IB, whereas mouse sPLA2-
IIA had about 6- to 10-fold lower a⁄nity [17]. In the present
work, mouse sPLA2-X showed a three-fold higher a⁄nity
compared to human sPLA2-IB in MC3T3E1 cells (Fig. 2),
suggesting that sPLA2-X is one of the high-a⁄nity ligands
for mouse PLA2R. Pro-sPLA2-X had a weaker binding po-
tency than its mature form, indicating that proteolytic remov-
al of the propeptide is required for the high-a⁄nity receptor
binding, as in the case of sPLA2-IB [24]. Because some inbred
mouse strains have a natural mutation in the sPLA2-IIA gene
[25,26], the contribution of sPLA2-IIA as a PLA2R ligand
could be much lower in mice.
We have previously shown a pivotal role of PLA2R in the
promotion of pro-in£ammatory cytokine synthesis during
murine endotoxic shock, based on the ¢ndings of reduced
cytokine production in PLA2R-de¢cient mice as well as in
indoxam-administered mice [15,16]. In the present study, the
sPLA2-X speci¢c binding was completely abrogated by the
de¢ciency in PLA2R (Fig. 5) and by the addition of indoxam
(Fig. 4B). Furthermore, our recent immunohistochemical
analysis with sPLA2-IIA-de¢cient mice revealed co-localiza-
tion of sPLA2-X and PLA2R in alveolar type II pneumocytes,
which are known to play a role in the production of various
cytokines and lipid mediators (Ikeda et al., unpublished ob-
servation). These ¢ndings suggest a potential involvement of
sPLA2-X in the receptor-mediated regulation of cytokine syn-
thesis under in£ammatory conditions. Since sPLA2-X induces
a potent release of fatty acids leading to eicosanoid formation
in several in£ammatory cells [19,20], the potential role of
PLA2R in this process should be examined in future work.
In particular, PLA2R might play a role in the internalization
and degradation of sPLA2-X to suppress its powerful enzy-
matic activity, as reported for snake venom sPLA2s [27]. Fi-
nally, further elucidation of PLA2R-mediated biological re-
sponses should enable us to assign more precise biological
roles to the growing family of mammalian sPLA2s.
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